title: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
abstract: The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of rituximab (RTX) [Roche] to submit evidence for the clinical and cost effectiveness of RTX as first-line maintenance treatment for patients with follicular non-Hodgkin's lymphoma (fNHL) whose disease has responded to induction therapy with RTX plus cytotoxic chemotherapy (R-CTX) in accordance with the Institute's Single Technology Appraisal (STA) process. The Liverpool Reviews and Implementation Group (LRiG) at the University of Liverpool was commissioned to act as the Evidence Review Group (ERG). This article summarizes the ERG's review of the evidence submitted by the manufacturer and provides a summary of the Appraisal Committee's (AC) decision. The clinical evidence was derived from a multi-centred, open-label, randomized phase III study (PRIMA) comparing first-line maintenance treatment with RTX with observation only in 1,018 patients with previously untreated advanced fNHL. Median time to event (MTE) for the primary endpoint of progression-free survival (PFS) in the RTX arm was not estimable due to data immaturity; median PFS in the observation arm was 48.36 months. A statistically significant benefit of RTX maintenance therapy for PFS was reported (hazard ratio [HR] 0.55, 95 % CI 0.44-0.68; p < 0.0001). Statistically significant differences in favour of RTX were also reported for a range of secondary endpoints. Assessment of overall survival benefit could be not made due to insufficient events. The ERG's main concern with the clinical-effectiveness data presented was their lack of maturity. The submitted incremental cost-effectiveness ratio was within the NICE threshold. The ERG questioned the model on a number of grounds, particularly the use of Markov methodology rather than patient simulations, the impact of patient age on the outcome and the projective PFS modelling. The ERG considered it impossible to draw firm conclusions regarding the clinical or cost effectiveness of the intervention as the dataset was as yet too immature. At a third meeting, the AC concluded that RTX could be recommended as first-line maintenance treatment for patients with fNHL whose disease has responded to induction R-CTX.
authors.affiliation: Liverpool Reviews and Implementation Group, University of Liverpool, 2nd Floor, Whelan Building, The Quadrangle, Brownlow Hill, Liverpool, L69 3 GB, UK. janette.greenhalgh@liverpool.ac.uk
authors.forename: Janette
authors.initials: J
authors.lastname: Greenhalgh
authors.forename: Adrian
authors.initials: A
authors.lastname: Bagust
authors.forename: Angela
authors.initials: A
authors.lastname: Boland
authors.forename: Michaela
authors.initials: M
authors.lastname: Blundell
authors.forename: James
authors.initials: J
authors.lastname: Oyee
authors.forename: Sophie
authors.initials: S
authors.lastname: Beale
authors.forename: Yenal
authors.initials: Y
authors.lastname: Dundar
authors.forename: Juliet
authors.initials: J
authors.lastname: Hockenhull
authors.forename: Chris
authors.initials: C
authors.lastname: Proudlove
authors.forename: Patrick
authors.initials: P
authors.lastname: Chu
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000191:economics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000191:economics; D008390:Markov Chains; D018803:Models, Economic; D000069283:Rituximab; D013534:Survival; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab